Therap Adv Gastroenterol

Therap Adv Gastroenterol

Country: Unknown

Publisher: Unknown

Publication Period: Unknown

388

Papers in Database

Journal Information
Publication Details
Additional Information

Subject Term Count: 1

Last Updated: Aug 05, 2025

Recent Papers

View All 388 Papers
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomen…

Li M, Chen S, Li S, Lv T, Li B, Shan S, Li M, Zeng N, Wang Q, Kong Y, Ma H, Zhao X, Ou X, You H, Du…

2024 PMID: 38250015
3/7
COI Funding
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel dis…

Nigam GB, Chatten K, Sharara A, Al-Taweel T, Alharbi O, Elamin H, Al Awadhi S, Annese V, Limdi JK.

2024 PMID: 38406794
4/7
COI Funding
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis tr…

Calafat M, Torres P, Tosca-Cuquerella J, Sánchez-Aldehuelo R, Rivero M, Iborra M, González-Vivo M, …

2024 PMID: 38187926
3/7
COI Funding
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>KRAS</i> mutation res…

Béchade D, Palmieri LJ, Bonhomme B, Pernot S, Léna J, Fonck M, Pesqué S, Boillet G, Italiano A, Ros…

2024 PMID: 38250014
3/7
COI Funding
Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

Brunet-Mas E, Garcia-Sagué B, Vela E, Melcarne L, Llovet LP, Pontes C, García-Iglesias P, Puy A, La…

2024 PMID: 38357537
4/7
COI Funding
COI Funding
New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases.

Park J, Park IS, Kim JH, Ji JH, Park SJ, Park JJ, Kim TI, Kim SW, Cheon JH.

2024 PMID: 38282956
3/7
COI Funding
Stricture dilation <i>via</i> balloon-assisted endoscopy in Crohn's disease: approach and intraprocedural outcomes with…

Halloran BP, Reeson M, Teshima C, Kroeker K, Huang V, Dieleman L, Holmes P, Baumgart DC, Wong K, Ho…

2024 PMID: 38425369
3/7
COI Funding
Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.

Anjie SI, Gecse KB, Ponsioen CY, Löwenberg M, D'Haens GR.

2024 PMID: 38406796
3/7
COI Funding